Autolus Therapeutics shares surge 11.95% after-hours following NICE draft guidance recommending Aucatzyl for B-ALL in the NHS.

Autolus Therapeutics surged 11.95% in after-hours trading following the U.K. National Institute for Health and Care Excellence (NICE) recommending its CAR T therapy Aucatzyl (obe-cel) for use in the National Health Service (NHS) to treat relapsed or refractory B-cell acute lymphoblastic leukemia. The approval, based on positive Phase 1 trial results showing high remission rates and a favorable safety profile for obe-cel, enables imminent NHS access and commercialization in England and Wales. Additional momentum came from the company’s presentation of promising clinical data for obe-cel at the American Society of Hematology Annual Meeting, highlighting its potential in hematological and autoimmune diseases. These developments reinforced investor confidence in Autolus’ therapeutic pipeline and market expansion, driving the significant after-hours gain.